Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record.

Molecular basis of ranolazine block of LQT‐3 mutant sodium channels: evidence for site of action

Open access
Fredj, Sandra, Sampson, Kevin J, Liu, Huajun, Kass, Robert S · 2006 · British Journal of Pharmacology

Abstract

We studied the effects of ranolazine, an antianginal agent with promise as an antiarrhythmic drug, on wild‐type (WT) and long QT syndrome variant 3 (LQT‐3) mutant Na+channels expressed in human embryonic kidney (HEK) 293 cells and knock‐in mouse cardiomyocytes and used site‐directed mutagenesis to probe the site of action of the drug. We find preferential ranolazine block of sustained vs peak Na+channel current for LQT‐3 mutant (ΔKPQ and Y1795C) channels (IC 50=15 vs 135 μM) with similar results obtained in HEK 293 cells and knock‐in myocytes. Ranolazine block of both peak and sustained Na+channel current is significantly reduced by mutation (F1760A) of a single residue previously shown to contribute critically to the binding site for local anesthetic (LA) molecules in the Na+channel. Ranolazine significantly decreases action potential duration (APD) at 50 and 90% repolarization by 23±5 and 27±3%, respectively, in ΔKPQ mouse ventricular myocytes but has little effect on APD of WT myocytes. Computational modeling of human cardiac myocyte electrical activity that incorporates our voltage‐clamp data predicts marked ranolazine‐induced APD shortening in cells expressing LQT‐3 mutant channels. Our results demonstrate for the first time the utility of ranolazine as a blocker of sustained Na+channel activity induced by inherited mutations that cause human disease and further, that these effects are very likely due to interactions of ranolazine with the receptor site for LA molecules in the sodium channel. British Journal of Pharmacology(2006)148, 16–24. doi:10.1038/sj.bjp.0706709

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0706709

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
Fredj, S., Sampson, K. J., Liu, H., & Kass, R. S.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2006-05
Volume
148
Issue
1
Pages
16-24
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1598538024
Cited by
168
References
0
FWCI
7.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular basis of ranolazine block of LQT‐3 mutant sodium channels: evidence for site of action. https://app.cochat.ai/papers/10.1038/sj.bjp.0706709
The paper
Fredj, S., Sampson, K. J., Liu, H., & Kass, R. S. (2006). Molecular basis of ranolazine block of LQT‐3 mutant sodium channels: evidence for site of action. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0706709

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.